Aclaris Therapeutics ACRS

No open-market insider buying or selling in the Form 4s filed since July 24, 2026.

• 8-KOct. 27, 2026, 5:25 p.m. ETView on SEC.gov

  Entry into a material definitive agreement · Financial statements and exhibits

  AI summary, unreviewedAclaris Therapeutics Prices Underwritten Offering of 7,785,714 Shares and Pre-Funded Warrants for Approximately $46.7 Million Net Proceeds at $3.50 per Share

• 424B5Oct. 27, 2026, 5:15 p.m. ETView on SEC.gov
• 8-KOct. 27, 2026, 6:06 a.m. ETView on SEC.gov

  Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits

  AI summary, unreviewedAclaris Therapeutics reports positive Phase 1b ATI-052 proof-of-concept data in atopic dermatitis and asthma, with cash of approximately $204.6 million as of September 30, 2026

• SCHEDULE 13GSept. 21, 2026, 4:09 p.m. ETView on SEC.gov
• SCHEDULE 13G/AAug. 14, 2026, 4:36 p.m. ETView on SEC.gov
• 8-KAug. 6, 2026, 5:15 p.m. ETView on SEC.gov

  Entry into a material definitive agreement · Financial statements and exhibits

• 10-QAug. 6, 2026, 4:31 p.m. ETView on SEC.gov
• 8-KAug. 6, 2026, 7:15 a.m. ETView on SEC.gov

  Results of operations and financial condition · Financial statements and exhibits